Pages that link to "Q29038503"

The following pages link to Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder (Q29038503):

Displaying 31 items.

• The OAuth 2.0 Web Authorization Protocol for the Internet Addiction Bioinformatics (IABio) Database (Q26751114) (← links)
• Biomarkers for drug development in early psychosis: Current issues and promising directions (Q26752612) (← links)
• Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role? (Q26864383) (← links)
• Evidence against dopamine D1/D2 receptor heteromers (Q27320053) (← links)
• Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism (Q28084069) (← links)
• SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C (Q30400003) (← links)
• Dopamine's Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive Disorders (Q35795738) (← links)
• Dopamine D1 receptor activation improves PCP-induced performance disruption in the 5C-CPT by reducing inappropriate responding (Q36618769) (← links)
• Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. (Q38699013) (← links)
• Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. (Q38762256) (← links)
• Phosphodiesterase 10 inhibitors in clinical development for CNS disorders (Q39029199) (← links)
• Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders (Q39284158) (← links)
• Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia (Q42367850) (← links)
• A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia (Q46330442) (← links)
• Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. (Q47550545) (← links)
• Dopamine D1 receptor subtype mediates acute stress-induced dendritic growth in excitatory neurons of the medial prefrontal cortex and contributes to suppression of stress susceptibility in mice. (Q47619041) (← links)
• Gs- versus Golf-dependent functional selectivity mediated by the dopamine D1 receptor. (Q49463637) (← links)
• Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance. (Q55656255) (← links)
• Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review (Q57040229) (← links)
• Nicotine improves probabilistic reward learning in wildtype but not alpha7 nAChR null mutants, yet alpha7 nAChR agonists do not improve probabilistic learning (Q57158354) (← links)
• A proof-of-principle study of the effect of combined haloperidol and levodopa administration on working memory-related brain activation in humans (Q57300662) (← links)
• Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis (Q58561523) (← links)
• Functional deficits in attenuated psychosis syndrome and related conditions: Current and future treatment options (Q64054968) (← links)
• Phosphodiesterase 1b (PDE1B) Regulates Spatial and Contextual Memory in Hippocampus (Q64241539) (← links)
• Review of pharmacologic treatment in cluster A personality disorders (Q89329311) (← links)
• Obligatory roles of dopamine D1 receptors in the dentate gyrus in antidepressant actions of a selective serotonin reuptake inhibitor, fluoxetine (Q90371588) (← links)
• D1 dopamine receptors intrinsic activity and functional selectivity affect working memory in prefrontal cortex (Q90372144) (← links)
• Cognitive impairment in substance use disorders (Q90782255) (← links)
• Dopaminergic modulation of olfactory-evoked motor output in sea lampreys (Petromyzon marinus L.). (Q91730999) (← links)
• Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation (Q98177426) (← links)
• Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia (Q102141673) (← links)